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Reproductive lawThe past 2 decades have seen a significant rise in cancer survival rates, and an increasing proportion of
survivors at reproductive age are interested in childbearing. Although assisted reproduction provides
physicians with an array of potential possibilities to help patients whose fertility is compromised by cancer
treatment, there is still a dearth of regulation regarding the application of this technology. The present
paper reviews the current options for fertility preservation, with a particular focus on the legal and ethical
challenges that confront providers of this type of care.
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The past 2 decades have seen a significant increase in cancer survival
rates, particularly for malignancies that commonly affect children and
young adults. The 5-year cancer survival rate among children improved
from 58% for patients diagnosed between 1975 and 1977 to 81% for
thosediagnosed between1999 and 2005 [1]. Survivors of childhood and
adolescent cancers now comprise 1 in every 570 individuals between
the ages of 20 and 34 years [2]. An increasing proportion of these
reproductive-aged survivors are interested in childbearing. Interviews
among young survivors suggest the possibility of biologic parenthood
after cancer is a powerful stimulus for recovery, and over 70% identify
their illness asa life experience that enhances their ability to successfully
parent a child [3].
Both the American Society of Clinical Oncology [4] and the
American Society for Reproductive Medicine [5] recommend that
cancer patients be informed about options for fertility preservation
at the time of diagnosis. Studies show, however, that only 50% of
childhood cancer survivors had discussed fertility with their physi-
cians, and half of the surveyed oncologists rarely or never raised the
issue of fertility preservation with their patients [6].
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The level of supporting evidence for treatments for fertility
preservation varies considerably, and each modality has distinct
advantages and limitations. The most well-established methods
include embryo cryopreservation and ovarian transposition in women
and sperm cryopreservation in men. Because fertility preservation is
an emerging field, most other options remain experimental. The
American Society for Reproductive Medicine recommends that
methods such as oocyte cryopreservation and ovarian tissue freezing
be offered only on an experimental basis under institutional review
board (IRB) approval [7].
2.1. Embryo cryopreservation
Embryo cryopreservation is the most established method for
female fertility preservation and is routinely used during in vitro
fertilization (IVF) cycles for the storage of surplus embryos. The
approach involves a 2–3-week delay in cancer treatment to allow
time for an IVF cycle, making it unsuitable for patients who require
immediate treatment. It also requires a male gamete source, thus
precluding its use in children and women without a partner who do
not wish to use donor sperm. Finally, there is theoretical concern that
the supraphysiologic levels of estradiol present during conventional
stimulation protocolsmay increase the riskof disease recurrence among
women with estrogen-sensitive tumors. A prospective trial [8] using
aromatase inhibitors in conjunction with gonadotropins to minimize
levels of circulating estrogen did not demonstrate an increase in disease
recurrence as compared with women who did not undergo a fertility
preserving procedure.. Published by Elsevier Ireland Ltd. All rights reserved.
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most successful method of fertility preservation. Approximately 75%
of embryos survive the freeze–thaw process, with reported pregnancy
rates of up to 30% per cycle, depending on the woman's age and
the total number of embryos transferred [9]. Higher embryo survival
rates approaching 90% have been reported after rapid freezing by
vitrification [10]. A large retrospective study [11] found live birth
rates to be independent of the time the embryos spent in storage—an
important factor for young patients who may undergo cryopreserva-
tion far in advance of their intended time of family planning.
2.2. Ovarian transposition
The treatmentof genital, intestinal, orurinary tractmalignanciesoften
involves pelvic radiation. Ovarian transposition (also called oophoropexy
or ovarian suspension) involves transposition of the ovaries above the
pelvic brim to minimize radiation-inflicted damage. The utero-ovarian
ligament and mesovarium are divided, but the fallopian tube is left
intact to retain the chance of spontaneous conception.
A 2003 meta-analysis [12] reported that 89% of women under the
age of 40 years resumed menstruation after ovarian transposition,
although most studies included in the meta-analysis did not address
subsequent pregnancy rates. Other studies have demonstrated resump-
tion of menstruation in 16%–90% of women, depending on the age
of the patient, the degree of scatter radiation, the radiation dose, and
whether the ovaries were shielded [13].
Should these patients require IVF in the future, transvaginal
oocyte retrieval may be difficult and an abdominal approach may be
required. Moreover, ovarian transposition offers no protection against
chemotherapy or whole-body irradiation and should not be used in
these situations.
2.3. Sperm cryopreservation
Like embryo cryopreservation, sperm cryopreservation is an estab-
lished technique that is frequently used as part of an IVF cycle. It should
be offered before chemotherapy, radiation, or surgery affecting the
male reproductive tract. Traditional recommendations involve banking
at least 3 semen samples with a 48-hour abstinence between samples,
but fewer specimens are often obtained when there is an urgent need
to initiate therapy. Spermcryopreservation canbeused in adultmenand
pubertal boys. If a young patient is unable to provide a specimen,
electroejaculation or surgical sperm extraction can be performed.
Sperm may still be cryopreserved after chemotherapy or radiation
prior to the onset of azoospermia, but the effect of these therapies on
the reproductive performance of sperm remains unclear. Increased
aneuploidy rates have been shown up to 18 months after chemo-
therapy for testicular cancer [14], prompting the recommendation
that men either cryopreserve sperm before chemotherapy or wait
18 months after treatment before pursuing fertility.
2.4. Oocyte cryopreservation
Oocyte cryopreservation, although experimental, is one of the few
available options for prepubertal girls and womenwho do not wish to
use donor sperm [15].
Oocytes can be cryopreserved at either the mature or the
immature stage. Mature oocytes are halted in metaphase of meiosis
II prior to fertilization. Because of their large size, water content,
and meiotic spindle, these oocytes are sensitive to cryodamage. The
efficiency of this strategy has improved significantly with the use
of rapid-freeze methods such as vitrification, which afford survival
rates as high as 90%, compared with rates of 50%–60% seen with
conventional slow-freeze methods [16]. Despite the concern that
damage to the meiotic spindle can increase aneuploidy rates, a study
[17] of 200 infants conceived after oocyte vitrification did not identifya higher incidence of congenital abnormalities compared with infants
conceived with standard IVF. While experienced centers report
delivery rates up to 57% [18], a 2006 meta-analysis reported an
overall live birth rate of 21.6% per embryo transfer [19]. It is worth
noting that these figures are not yet typical and a more average
success rate may be 2–3% per thawed oocyte [20].
Retrieval of immature oocytes with in vitro maturation and
subsequent cryopreservation can be done without hormonal stimu-
lation, thus avoiding delays in cancer treatment and the presence of
supraphysiologic estradiol levels in women with hormone-sensitive
tumors. Immature oocytes are more resistant to injury because they
lack a metaphase spindle and contain diffuse chromatin surrounded
by a nuclear membrane. Despite the superior survival rate, the
inefficiency of in vitro maturation results in a final mature oocyte
yield similar to that obtained with cryopreservation of metaphase II
oocytes. There are few reported live births among patients treated
with oocyte cryopreservation and in vitro maturation [21].
2.5. Ovarian suppression
Suppression of folliculogenesis with gonadotropin-releasing hor-
mone agonists (GnRH-a) for fertility preservation remains contro-
versial. An early animal study [22] indicated that pretreatment
with GnRH-a protects against gonadal damage induced by cytotoxic
chemotherapy. Although nonrandomized human studies have sup-
ported the protective effect of GnRH-a in women with Hodgkin's
lymphoma and breast cancer [23], a randomized study [24] of 18
women with Hodgkin's disease failed to demonstrate this effect.
Critics of GnRH-a cite a lack of biologic plausibility, because over
90% of the adult ovary is comprised of primordial follicles that
are recruited through a follicle-stimulating-hormone-independent
mechanism and that are, therefore, unresponsive to GnRH-a [25].
Conserving the remaining 10% of the follicle pool, although possible, is
unlikely to significantly impact ovarian reserve. The American Society
of Clinical Oncology concludes that “there is insufficient evidence that
GnRH-a protects gonadal function from gonadotoxic agents” [4]. Large
randomized trials addressing this issue are currently underway.
2.6. Ovarian tissue freezing
Ovarian cryopreservation involves the laparoscopic removal and
cryopreservation of ovarian cortical tissue followed by subsequent
transplantation at the time of desired conception. The technique offers
many advantages: Tissue can be obtained at any point in themenstrual
cycle without delay of cancer treatment and no male gamete source is
required,making it an option for children orwomenwho do not desire
donor sperm. Follicular loss rates of up to 66% secondary to ischemia
upon initial transplantation limit the usefulness of this strategy in
patients with a diminished ovarian reserve [26]. A second concern is
that transplanted tissue may result in the reseeding of cancer. A
thorough histologic and immunohistochemical evaluation is therefore
recommended before and after ovarian cryopreservation to screen
for malignancy.
The ovarian graft can be transplanted to an orthotopic site in the
ovarian fossa or to a heterotopic site in the forearm or abdominal
wall. Heterotopic transplants do not require general anesthesia but
eliminate the chance for a spontaneous pregnancy. A review of the
literature [27] identified 13 live births after orthotopic transplantation.
Oktay et al. [28] described the development of a 4-cell embryo
following stimulation of a heterotopic transplant in a woman with
breast cancer, but no ongoing pregnancies have yet been reported.
2.7. Testicular tissue freezing
At present, the only possibility for fertility preservation in
prepubertal boys is cryopreservation of spermatogonial stem cells
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stem cells recolonize the seminiferous tubules and reinitiate sper-
matogenesis. This process has resulted in live births in mice [29], but
remains theoretical in humans. The efficacy of the freezing protocols,
the long-term safety, the reproductive outcomes, the risk of malignant
contamination, and the damage to the recipient testes all require
further investigation before the technology can be clinically applied.
3. Ethical considerations
3.1. Assisted reproduction in cancer patients
An often cited ethical consideration when treating cancer survivors
is whether the act of reproduction poses a risk to the potential offspring,
a dilemma that canbe simplified to a conflict betweenpatient autonomy
and provider non-maleficence [30].
Thefirst issue iswhether childrenof cancer survivors are themselves
at increased risk of cancer. The literature does not support an increase
in the risk of malignancy among the offspring of cancer survivors [31],
and a hereditary cancer risk should therefore not be used as a
justification forwithholding assisted reproduction from cancer patients.
A second concern is that the premature death of a cancer survivor
would unfairly leave a child bereft of a parent. Although some have
suggested it unethical to enable reproduction for individuals whose
lifespan may be reduced by illness, most ethicists consider this an
insufficient argument to deny cancer patients infertility treatment.
Given that many children lead meaningful lives despite suffering the
loss of a parent, the Ethics Committee of the American Society for
Reproductive Medicine concludes that the risks to children from
the possibility of being raised by a single parent “are not a sufficient
reason to deny cancer patients assistance in reproducing” [5].
This issue is more contentious for single cancer survivors whomay
leave an orphaned child should they suffer a premature death. A
recent series [32] reported that 16 of 35 (37%) female cancer patients
were single at the time of fertility preservation, indicating a significant
interest in these technologies on the part of single women. A number
of arguments can be made for the provision of fertility preservation
therapies to single cancer survivors. An individual's relationship
status is dynamic—a woman who is single at the time of fertility
preservation may be coupled by the time she is ready to procreate.
Moreover, a significant self-selection process is likely to occur in that
the womenwho aremost likely to return for the use of stored gametes
or ovarian tissue are those who are healthy enough to withstand the
physiologic demands of pregnancy.
3.2. Resource allocation
A common debate surrounding infertility and fertility preservation
is that of access to care: Is prevention of infertility a just and prudent
use of resources? The answer depends on themanner in which society
views the concept of procreative liberty. As described by John
Robertson [33], the right to reproduce has long been considered a
“negative right”, meaning that the state should not interfere with an
individual's ability to reproduce through mandatory sterilization or
by denying access to fertility treatment. It has not yet, however, been
granted the status of a “positive right”, in that the state should provide
resources to enable an otherwise infertile individual to procreate.
Daniel Brock [34] describes health care as a means to “afford
individuals access to the normal range of opportunities in society”,
whether it be the ability to care for themselves, hold productive
employment, or maintain interpersonal relationships. Extending
procreative liberty to a “positive right” would require expanding
this concept to include the ability to parent a child—an experience
that is considered the norm in most societies [35,36]. Backhus and
Zoloth [37] suggest that this decision may be clearer in the case ofcancer survivors, arguing that “there is a duty to prevent damage to or
repair that which is damaged by [cancer] treatment”.
A practical extension of this argument is that insurance companies
are ethically obligated to cover fertility preservation in cancer patients
because of impending iatrogenic damage to the reproductive organs.
Unfortunately, insurance coverage for fertility preservation is scarce
and there are currently no state or federal mandates in the USA
that specifically address the issue. Even in the few states that have
mandated coverage for general infertility services, cancer patients are
often excluded because they are not technically “infertile” at the time
when they seek care [38]. This is inconsistent with existing policies
that offer insurance coverage for other types of iatrogenic injury, such
as reconstructive breast surgery after mastectomy for breast cancer
[39]. There is little ethical justification to withhold insurance coverage
for fertility preservation technologies in states that already mandate
coverage of infertility services.
4. Legal considerations
4.1. Consent and assent in minors
The first guidelines for the ethical study of drugs in children were
published by the American Academy of Pediatrics in 1977 [40]. These
guidelines describe the concept of “minimal risk”, which is defined as
risk similar to that encountered in the child's usual daily life—
including interventions such as physical examinations, venipuncture,
and urine collection. By this definition, a majority of available fertility
preservation procedures are categorized as posing a “greater than
minimal risk” given that they involve invasive procedures. Addition-
ally, many currently available options for fertility preservation among
minors remain experimental and are therefore only offered under
IRB-approved research protocols.
The updated 1995 American Academy of Pediatrics guidelines [41]
state that research in children involving greater than minimal risk is
permissible so long as: (1) The risks are justified by the anticipated
benefits, (2) the anticipated benefit is at least as favorable as that
provided by alternatives, and (3) appropriate permission (agreement
of a parent to participation of their child in research) and assent
(agreement to participate in a procedure by a minor over the age of
7 but not yet qualified to give consent) has been obtained. It is worth
noting that by these criteria, a child with the ability to understand and
give assent (generally around 8 years of age) can refuse participation
in a fertility-sparing procedure regardless of parental wishes.
Many advocate a 2-stage consent process that separates the issue
of whether to store gametes from the decision of whether to use the
stored gametes. While the first decision must be made at the time of
cancer diagnosis, the decision regarding the use of stored gametes can
be deferred until the patient has reached adulthood.
4.2. Disposition of gametes
Excepting cases of planned gametedonation, spermand eggs remain
the sole possession of the person from whom they were removed.
An embryo, however, could “belong” to both the egg and the sperm
donor. Conflict arises when an embryo is created for reproduction
and the parties involved subsequently disagree about its use, as in the
case of separation, divorce, or death.
The US courts have held that the embryo should not be used for
reproduction unless the intent of both parties is that reproduction
should occur. In the 2001 divorce case of Davis v. Davis regarding
embryo disposition, the court held that “ordinarily, the party wishing
to avoid procreation should prevail, assuming that the other party has
a reasonable possibility of achieving parenthood by means other than
use of the preembryos in question. If no other reasonable alternatives
exist, then the argument in favor of using the preembryos to achieve
pregnancy should be considered” [42].
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fertility preservation, both in the USA and abroad. An example is the
2007 case of Natalie Evans, a British woman who had been rendered
infertile by cancer treatment and lost her attempt to prevent the
destruction of embryos that had been created with her eggs and the
sperm of her former partner [43]. The UK's Human Fertilisation and
Embryology Authority provides standard consent forms that stipulate
the disposition of embryos in the case of death, but without specifying
disposition in cases of separation or divorce. The wording of the
1995 Australian Infertility Treatment Act was similarly unclear,
allowing gamete donors to withdraw consent before a “procedure”
is carried out, without specifying which procedure—fertilization or
embryo transfer—was being referred to. A more recent version of
the Australian Infertility Treatment Act stipulates that a donor may
not withdraw his or her consent once an embryo is formed from
donated gametes [44].
As a result of this legal ambiguity, many infertility clinics have
created contracts specifying how embryos will be managed if the
parties refuse to pay storage fees, disagree on future use, die, or
divorce. When such contracts exist, the courts have generally upheld
them on the theory that the initial agreement of the parties should be
carried out. A 2003 review by Schuster et al. [45] discusses guidelines
for contracts addressing disposition of semen and embryos, suggesting
that they be unambiguous, consistent with public policy, and clearly
state the duration of the agreement, the intents of both parties signing
the agreement, and the responsibilities of the cryopreservation center
in the storage and disposition of the cryopreserved material.
The relevance of these issues in cancer patients is illustrated by a
2009 study [46] that explored the rates of divorce or separation among
couples where 1 partner was affected with cancer. The investigators
reported a 6-fold increased risk of separationwhen the affected spouse
was the woman (20.8% versus 2.9%, Pb0.001). Further confusion may
arise in cases where an adolescent woman cryopreserves embryos
with sperm from a partner with whom she later parts. Many clinics,
including our own, suggest that these young women consider
fertilizing half of the embryos with their partner's sperm and the
other half with donor sperm to preserve their right to use the embryos
regardless of the relationship outcome. Couples who are embarking
upon gamete storage should be made aware of these possibilities and
referred to legal counsel to create contracts specifying their wishes
for gamete disposition.
4.3. Posthumous reproduction
A more controversial legal issue is the use an individual's gametes
after their death, also termed posthumous reproduction. There are
wide differences in national law concerning this subject, ranging from
complete prohibition in some countries to permissive rules in others,
often intersecting with religious belief. Roman Catholicism rejects the
procedure on the same grounds as its rejection of assisted reproduc-
tion technologies: the separation of human reproduction from sexual
intercourse. Islam also rejects the procedure because it takes place
after the end of the marital term. Jewish law, by contrast, does permit
posthumous reproduction [47].
The 2001 case of Woodward v. Commissioner of Social Security
was one of the highest-profile legal cases involving posthumous
reproduction in the USA. The case was brought by a widow who gave
birth to twins by intrauterine insemination with her husband's
cryopreserved sperm 2 years after his death from leukemia. When she
attempted to file for social security benefits for her children, her claim
was rejected on the basis that the children were not heirs. The case
was ultimately appealed to the Massachusetts Supreme Court, which
determined that even though the plaintiff's husband had frozen his
sperm, there was no evidence demonstrating his consent to using
the sperm to conceive a child after his death and the children could
therefore not be considered heirs [48].The most rigorous professional guidelines on this topic were
published in 2006 by the European Society for Human Reproduction
and Embryology [47]. These state that posthumous reproduction is
acceptable only if (1) the decision is made by the surviving partner in
the relationship, (2) written consent regarding the use of gametes
was given by the deceased at the time of storage, and (3) the surviving
partner waits a minimum of 1 year to allow time for grieving before
using the gametes. If these clauses are met, children born from
posthumous reproduction should not be discriminated against as
compared with those born prior to the death of a parent.
5. Conclusions
Assisted reproduction has been advancing at an extremely rapid
rate, providing physicians with an array of emerging possibilities to
help patients whose fertility is compromised by malignancy or cancer
treatment. In the face of this rapid progress, however, there is still a
dearth of regulation regarding the application of this technology. The
implementation of a consistent legal and ethical standard will likely
require not only the cooperation of professional organizations and the
legal community, but also the input of the patients themselves.
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